Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered
approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the
drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a
second period (Period 2) will be conducted. In Period 2, a single dose of drug will be
administered approximately 4 hours prior to hemodialysis.